Interim report January-June 2009

• Group revenues from sales of goods and royalties amounted to 721 (630) MSEK. • Earnings per share amounted to 5.95 (0.32) SEK. • Operating income amounted to 625 (39) MSEK. • Revenues within the Esthetics product area amounted to 591 (516) MSEK and operating income was 142 (118) MSEK. • Net income after tax amounted to 592 (32) MSEK. April - June • Group revenues from sales of goods and royalties amounted to 382 (341) MSEK during the second quarter and operating income amounted to 571 (29) MSEK. Operating income for the Esthetics product area amounted to 92 (63) MSEK and 498 (-8) MSEK for the Hospital Healthcare product area. • Net income after tax amounted to 550 (22) MSEK during the second quarter. • In April 2009 Q-Med AB and Oceana Therapeutics, LCC., based in the US, entered into global agreements regarding commercialization rights to Deflux® and Solesta™. As part of the transaction Oceana acquired Q-Med Scandinavia, Inc. In June 2009 Q-Med received 60 MUSD, corresponding to 502 MSEK and additional 15 MSEK for Oceana’s share of the clinical trial costs, which under the agreements the parties will share. The net revenue from the divestment, that is after the deduction of acquisition costs, together with payment for the clinical trial costs, amounted to 496 MSEK and this has been reported under Other operating revenues. Important events after the end of the period • Q-Med’s Premarket Approval (PMA) application for Durolane™ will be discussed on August 19 2009, at a public meeting of the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee. The panel is expected to consider the clinical trial results Q-Med submitted to support the approval and labelling of Durolane, a single dose product for the treatment of pain caused by osteoarthritis of the knee.